News for Adaptive Biotechnologies Corporation (ADPT)

On Friday, Cathie Wood-led Ark Invest made significant trades involving Beam Therapeutics Inc. BEAM, Nu Holdings Ltd. NU, MercadoLibre Inc. MELI, and Adaptive B...

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

Earnings Call Insights: Adaptive Biotechnologies (NASDAQ:ADPT) Q4 2024Management ViewCEO Chad Robins highlighted a strong year for Adaptive Biotechnologies,...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2024 Results Conference Call February 11, 2025 4:30 PM ETCompany ParticipantsKarina Calzadilla - Head...

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 11.54% and 2.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[533426]**

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stands against...

We recently compiled a list of the Billionaire Andreas Halvorsen's Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Adaptive Biotechnologies Corporation (NASDAQ:ADPT...

Here is how Adaptive Biotechnologies (ADPT) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.

Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cathie Wood-led Ark Invest sold 140,518 shares of Palantir and bought shares of Tempus AI Inc. The total value of the trades is about $9.1 million.

Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT.

SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ( ADPT), a commercial stage biotechnology company that aims to translate the g

Adaptive Biotechnologies stock hits 52-week high at $7.08

SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ( ADPT), a commercial stage biotechnology company that aims to translate the g

**media[504480]**

Cathie Wood's ARK offloads Tesla stock, buys into AMD and GitLab